(function(){ var content_array=["

關于 Gene Solutions<\/b><\/p> \n

Gene Solutions 是一家亞洲跨國生物科技公司，在利用先進的人工智能 (AI) 和 ctDNA 技術提供創新癌癥檢測解決方案方面處于領先地位。公司與東南亞 4,500 多家醫院和診所合作，擁有一支由約 250 名生物學專家和技術人員組成的專業團隊，員工總數達 700 人。<\/p> \n

Gene Solutions 已在東南亞地區發表了 50 多篇同行評審的論文，并開展了 50 多項多中心研究，其自主研發成果以及位于新加坡和越南的 CAP 認證的新一代測序 (NGS) 實驗室備受認可。通過將多維基因組學與人工智能驅動的方法相結合，公司致力于變革癌癥治療，令更多癌癥患者受益。<\/p> \n

    \n
  1. Hoang, V.-A.N. et al. (2025) 'Real-World utilization and performance of circulating tumor DNA monitoring to predict recurrence in solid tumors,' JCO Oncology Advances, Volume 2. DOI: 10.1200\/OA-24-00084<\/span><\/li> \n
  2. Huang, J. et al. (2022) 'Cancer incidence and mortality in Asian countries: a trend analysis,' Cancer Control, 29. DOI:10.1177\/10732748221095955.<\/span><\/li> \n
  3. Sharma, R. et al. (2024) 'Temporal patterns of cancer burden in Asia<\/span>, 1990-2019: a systematic examination for the Global Burden of Disease 2019 study,' The Lancet Regional Health - Southeast Asia<\/span>, 21, p. 100333. DOI:10.1016\/j.lansea.2023.100333.<\/span><\/li> \n
  4. Kobayashi, S. et al. (2025) 'Japan<\/span> society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing,' International Journal of Clinical Oncology [Preprint]. DOI:10.1007\/s10147-024-02683-0.<\/span><\/li> \n
  5. Use of Circulating Tumor DNA for Curative-Intent Solid Tumor Drug Development. (2024). In Guidance for Industry [Clinical\/Medical]. FDA Guidances, Content current as of: 01\/17\/2025.<\/span><\/li> \n<\/ol> \n
    \n<\/div>"]; $("#dvExtra").html(content_array[0]);})();
    <center id="kgssg"></center>
    <center id="kgssg"><wbr id="kgssg"></wbr></center>
    <noscript id="kgssg"><option id="kgssg"></option></noscript><optgroup id="kgssg"><wbr id="kgssg"></wbr></optgroup><optgroup id="kgssg"></optgroup>
    <optgroup id="kgssg"><div id="kgssg"></div></optgroup>
    <center id="kgssg"><div id="kgssg"></div></center>
    <center id="kgssg"></center>
    久久久亚洲欧洲日产国码二区